Translational Pharmacologic Efficacy Studies of Glial Growth Factor 2 (GGF2) in Spinal Cord Injury Models and in the Veterinary Clinical Setting

Abstract

The work performed under this grant evaluated the efficacy of Glial Growth Factor 2 (GGF2), a member for the neuregulin family, as a spinal cord injury (SCI) therapeutic. The research expanded on previous work and extended these studies to determine if GGF2 should be advanced into human clinical studies for SCI. GGF2 s optimal dosage was examined using a model of rodent SCI and testing several dose levels delivered either subcutaneously (SC) or intravenously (IV). Optimized dosing was determined to be by a SC route, and subsequent studies evaluated recovery of function by monitoring bladder function, muscle volume changes, and motor function in SCI rodent models of various severities. Additionally, safety and tolerability was explored in naive canines, and followed by a clinical trial for safety in dogs with SCI.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Jul 01, 2015
Accession Number
ADA624532

Entities

People

  • Anindita Ganguly
  • Anthony O. Caggiano

Tags

DTIC Thesaurus Topics

  • Biological Sciences
  • Blood
  • Chemical Synthesis
  • Chemistry
  • Detectors
  • Growth Factors
  • Health Services
  • Medical Personnel
  • Nervous System
  • Spinal Cord
  • Spinal Injuries
  • Spine
  • Statistical Analysis
  • Surgery
  • Therapy
  • Wounds And Injuries

Fields of Study

  • Medicine

Readers

  • Canine Service Warrior Training Program for Wounded Warriors in the Veterinary Industry, Supported by Donors.
  • Neurotrauma and Rehabilitation Medicine.